¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.

IF 1.2 Q2 MEDICINE, GENERAL & INTERNAL

Tidsskrift for Den Norske Laegeforening Pub Date : 2024-07-30 Print Date: 2024-08-20 DOI:10.4045/tidsskr.23.0478

Rune Sundset, Hege Sagstuen Haugnes, Alexander Perez, Ola Engelsen, Ida H H Fosseide, Miguel J Castillejo, Trond Velde Bogsrud

{"title":"¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.","authors":"Rune Sundset, Hege Sagstuen Haugnes, Alexander Perez, Ola Engelsen, Ida H H Fosseide, Miguel J Castillejo, Trond Velde Bogsrud","doi":"10.4045/tidsskr.23.0478","DOIUrl":null,"url":null,"abstract":"Background: Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.Case presentation: A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.Interpretation: Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.","PeriodicalId":23123,"journal":{"name":"Tidsskrift for Den Norske Laegeforening","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tidsskrift for Den Norske Laegeforening","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4045/tidsskr.23.0478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/20 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.

Case presentation: A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.

Interpretation: Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.

查看原文本刊更多论文

¹⁷⁷Lu-PSMA放射性配体疗法治疗转移性阉割耐药前列腺癌。

背景：用[¹⁷⁷Lu]PSMA放射性配体治疗阉割耐药转移性前列腺癌：用[¹⁷⁷Lu]PSMA放射性配体治疗耐药转移性前列腺癌：一名七十多岁的转移性前列腺癌患者接受了四年的阉割治疗，出现了阉割抵抗性疾病。使用[⁶⁸Ga]PSMA-11 的 PET/CT 显示转移淋巴结的高摄取率。该患者接受了 7.4 GBq [¹⁷⁷Lu]PSMA-I&T （芬兰 Curium 公司）的治疗，共五次，每次间隔五周。第一次治疗五周后，p-PSA 从 154 微克/升降至 53 微克/升。第五次治疗五周后，p-PSA 为 1.8 µg/L。[⁶⁸Ga]PSMA-11 PET/CT 显示转移灶的大小显著缩小，最大的直径从 10 毫米缩小到 4 毫米。第五次治疗 7 个月后，p-PSA 升至 14.3 µg/L，[⁶⁸Ga]PSMA-11 PET/ CT 显示出更多的骨骼转移灶，而淋巴结转移灶保持不变。因此，治疗对转移灶有良好但暂时的效果：解读：使用[¹⁷⁷Lu]PSMA放射性配体治疗可使转移灶暂时消退。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tidsskrift for Den Norske Laegeforening MEDICINE, GENERAL & INTERNAL-

CiteScore

0.60

自引率

18.20%

发文量

593

审稿时长

28 weeks